Price to Book Value (P/BV)
since 2005
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Price to FCFE (P/FCFE)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Gilead Sciences Inc., P/BV, long-term trends, calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Total Gilead stockholders’ equity1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2011 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 3, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Gilead Sciences Inc. Annual Report.
The share price of the company displayed a general upward trajectory from 2006 through 2015, moving from $15.03 to a peak of $104.43 in February 2015. Following this peak, the share price experienced fluctuations and a downward trend until 2021, declining to $62.79. In the subsequent years up to February 2025, the share price showed recovery and volatility, reaching $114.31 by the latest period.
The book value per share (BVPS) exhibited consistent growth over the analyzed periods, starting at $1.64 in 2006 and increasing steadily to $17.83 by 2020. There was a slight decline to $14.49 in 2021 before growth resumed, reaching $18.33 in 2023. However, a decline to $15.52 was observed by February 2025.
The Price to Book Value (P/BV) ratio demonstrated significant volatility throughout the periods. Initially, the ratio was notably high at 18.07 in 2007, before declining sharply in subsequent years. Between 2009 and 2016, the P/BV ratio fluctuated between approximately 4.88 and 11.36, indicating varying market valuation relative to the book value per share. From 2017 to 2025, the ratio generally remained below 7.5, with some volatility, reflecting periodic shifts in investor sentiment and market conditions relative to the company's book value.
- Share Price
- Long-term growth to 2015 peak, followed by a downward trend and subsequent recovery with notable volatility.
- Book Value per Share (BVPS)
- Consistent growth overall with minor declines in 2021 and 2025, indicating steady enhancement of net asset value per share.
- Price to Book Value (P/BV) Ratio
- Highly volatile early years with a notable peak in 2007, followed by relative stabilization at lower levels, suggesting changes in market valuation dynamics and perceptions over time.
Comparison to Competitors
Gilead Sciences Inc., P/BV, long-term trends, comparison to competitors
| Gilead Sciences Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | ||||||||||||
| Feb 23, 2024 | ||||||||||||
| Feb 22, 2023 | ||||||||||||
| Feb 23, 2022 | ||||||||||||
| Feb 25, 2021 | ||||||||||||
| Feb 25, 2020 | ||||||||||||
| Feb 26, 2019 | ||||||||||||
| Feb 27, 2018 | ||||||||||||
| Feb 27, 2017 | ||||||||||||
| Feb 24, 2016 | ||||||||||||
| Feb 25, 2015 | ||||||||||||
| Feb 25, 2014 | ||||||||||||
| Feb 27, 2013 | ||||||||||||
| Feb 23, 2012 | ||||||||||||
| Feb 28, 2011 | ||||||||||||
| Mar 1, 2010 | ||||||||||||
| Feb 27, 2009 | ||||||||||||
| Feb 27, 2008 | ||||||||||||
| Feb 27, 2007 | ||||||||||||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Gilead Sciences Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Gilead Sciences Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 28, 2025 | ||
| Feb 23, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 25, 2021 | ||
| Feb 25, 2020 | ||
| Feb 26, 2019 | ||
| Feb 27, 2018 | ||
| Feb 27, 2017 | ||
| Feb 24, 2016 | ||
| Feb 25, 2015 | ||
| Feb 25, 2014 | ||
| Feb 27, 2013 | ||
| Feb 23, 2012 | ||
| Feb 28, 2011 | ||
| Mar 1, 2010 | ||
| Feb 27, 2009 | ||
| Feb 27, 2008 | ||
| Feb 27, 2007 | ||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Gilead Sciences Inc., P/BV, long-term trends, comparison to industry (health care)
| Gilead Sciences Inc. | Health Care | |
|---|---|---|
| Feb 28, 2025 | ||
| Feb 23, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 25, 2021 | ||
| Feb 25, 2020 | ||
| Feb 26, 2019 | ||
| Feb 27, 2018 | ||
| Feb 27, 2017 | ||
| Feb 24, 2016 | ||
| Feb 25, 2015 | ||
| Feb 25, 2014 | ||
| Feb 27, 2013 | ||
| Feb 23, 2012 | ||
| Feb 28, 2011 | ||
| Mar 1, 2010 | ||
| Feb 27, 2009 | ||
| Feb 27, 2008 | ||
| Feb 27, 2007 | ||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).